The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance and delivering strong returns.
Even among industry leaders, some companies shine bright, and we built StockStory to help you find them. That said, here are three Nasdaq 100 stocks driving the future of tech.
Rocket Lab (RKLB)
Market Cap: $66.44 billion
Becoming the first private company in the Southern Hemisphere to reach space, Rocket Lab (NASDAQ: RKLB) offers rockets designed for launching small satellites.
Why Is RKLB a Top Pick?
- Annual revenue growth of 55.1% over the past two years was outstanding, reflecting market share gains this cycle
- Operating margin improvement of 111.4 percentage points over the last five years demonstrates its ability to scale efficiently
- Cash-burning tendencies have improved over the last five years, showing it could become financially independent one day
At $99.45 per share, Rocket Lab trades at 62.6x forward price-to-sales. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
Intuitive Surgical (ISRG)
Market Cap: $146.2 billion
Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ: ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties.
Why Does ISRG Catch Our Eye?
- Annual revenue growth of 20.2% over the last two years was superb and indicates its market share increased during this cycle
- Share repurchases over the last five years enabled its annual earnings per share growth of 21.3% to outpace its revenue gains
- Robust free cash flow margin of 19.6% gives it many options for capital deployment, and its rising cash conversion increases its margin of safety
Intuitive Surgical’s stock price of $402 implies a valuation ratio of 37.3x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
DexCom (DXCM)
Market Cap: $29.04 billion
Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ: DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.
Why Is DXCM a Good Business?
- Core business can prosper without any help from acquisitions as its organic revenue growth averaged 12.5% over the past two years
- Free cash flow margin expanded by 26 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Rising returns on capital show management is finding more attractive investment opportunities
DexCom is trading at $67.31 per share, or 25.2x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
